Published in J Clin Oncol on March 18, 2013
Reply to A. Grothey et al and R.S. Midgley et al. J Clin Oncol (2013) 0.75
Reply to M. Gallén et al and R.S. Midgley et al. J Clin Oncol (2013) 0.75
Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought. J Clin Oncol (2012) 2.45
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med (2004) 13.34
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet (2007) 9.23
Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet (2012) 6.25
Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet (2010) 4.20
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol (2013) 2.90
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet (2009) 2.59
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet (2011) 2.47
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol (2010) 2.32
Open access chemical and clinical probes to support drug discovery. Nat Chem Biol (2009) 2.28
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
The challenge of cancer control in Africa. Nat Rev Cancer (2008) 1.71
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol (2004) 1.54
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol (2002) 1.52
A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology (2009) 1.46
Arginine methylation controls growth regulation by E2F-1. EMBO J (2012) 1.44
Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J Clin Oncol (2010) 1.34
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol (2009) 1.15
Single-dose clinical pharmacokinetic studies of gefitinib. Clin Pharmacokinet (2005) 1.14
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene (2002) 1.08
Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13. Hum Mol Genet (2011) 1.07
Capecitabine: have we got the dose right? Nat Clin Pract Oncol (2008) 1.02
Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nat Clin Pract Oncol (2005) 0.99
Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol (2004) 0.99
A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. Clin Colorectal Cancer (2003) 0.98
EnROL: a multicentre randomised trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme. BMC Cancer (2012) 0.92
Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther (2002) 0.89
Challenges of cancer control in developing countries: current status and future perspective. Future Oncol (2011) 0.87
CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des (2003) 0.86
Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins. J Drug Target (2003) 0.85
Colorectal cancer. Acta Oncol (2003) 0.85
Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol (2009) 0.84
Tobacco: deadly in any form or disguise. Lancet (2006) 0.83
Roles of tetrahydrobiopterin in promoting tumor angiogenesis. Am J Pathol (2010) 0.82
Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector. Int J Cancer (2003) 0.81
Immunotherapy for colorectal cancer. Expert Rev Anticancer Ther (2003) 0.80
Ras as a target in cancer therapy. Crit Rev Oncol Hematol (2002) 0.80
Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC. Nat Rev Clin Oncol (2009) 0.80
Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Sci (2006) 0.80
Gene therapy for colorectal cancer. Br Med Bull (2002) 0.79
Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver. Semin Oncol (2010) 0.79
The nitroreductase/CB1954 enzyme-prodrug system. Methods Mol Med (2004) 0.78
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Clin Colorectal Cancer (2013) 0.78
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. Invest New Drugs (2013) 0.76
Quinone oxidoreductase-2-mediated prodrug cancer therapy. Sci Transl Med (2010) 0.76
Gene profiling in early stage disease. Cancer J (2010) 0.76
Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. J Drug Target (2007) 0.76
Health diplomacy: a new approach to the Muslim world? Global Health (2014) 0.75
Malignant peritoneal mesothelioma. Is there a new treatment? Rare Tumors (2009) 0.75
Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer? Nat Rev Clin Oncol (2010) 0.75
Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet (2005) 0.75
EUFEPS report. Contribution of academic research to discovery and development of medicines: current status and future opportunities. Eur J Pharm Sci (2005) 0.75
Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments. Expert Opin Drug Metab Toxicol (2015) 0.75
Identification of an oligopeptide binding to hepatocellular carcinoma. Oncology (2007) 0.75
The emergence of 'omics for the management of colorectal cancer. Curr Opin Oncol (2011) 0.75
Clinical experience with adenovirus in cancer therapy. Curr Opin Mol Ther (2002) 0.75